KNOWLEDGE BANK

Interviews

Datamonitor

Analyst
include the changing patent laws as countries aim to become more TRIPS compliant with India updating its law recently and China in the process of doing so through the WTO Increasing globalization of the generics market with Indian companies becoming involved in Europe and the US and vice versa will also provide an opportunity for generics companies

Articles

Computational Approach towards Designing Potent Inhibitors for Tuberculosis

Mycobacterium tuberculosis Mtbis one of the major infectious diseases posing a major threat to many developing countries including India It has been a daunting task for researchers and scientists to design and develop drugs that possess the potential to inhibit the disease in a specific manner without exhibiting side effects in humans Presently there are four drugs

Research Insights

Interpretable Machine Learning for High-dimensional Trajectories of Aging Health

We have built a computational model for individual aging trajectories of health and survival which contains physical functional and biological variables and is conditioned on demographic lifestyle and medical background information We combine techniques of modern machine learning with an interpretable interaction network where health

Case Studies

Heat Stable Hepatitis B vaccine

Partner Since Arecor has collaborated with PATH an international global health nonprofit organisation on the development of heat stable vaccines using the ArestatT technology Stabilisation of hepatitis B vaccine one of the many vaccines successfully st

Techno Trends

China's Regulatory Challenges Signal a Shift in Drug Approval Processes

Chinas evolving drug approval processes are impacting pharmaceutical companies and their strategies in the market

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Kinase Inhibitors as Antiviral Agents

Thanigaimalai Pillaiyar

Thanigaimalai Pillaiyar is working as an independent junior research group leader and establishing a research group at the Tübingen Center for Academic Drug Discovery (TüCAD2), University of Tübingen. His research interests include medicinal chemistry of orphan G protein-coupled receptors (GPCRs), synthetic organic chemistry, and dual SARS-CoV-2 Mpro-kinase inhibitors.

 

Stefan Laufer

Stefan Laufer is Professor for Pharmaceutical/Medicinal Chemistry at Tuebingen University and chairs the TüCAD2. His research interests are anti inflammatory and cancer drug discovery. He authored more than 500 publications, 15 books/book chapters and is inventor in 42 patent families with >330 national applications. 4 compounds from his lab made it to first into man studies.

 

2

Nanotechnology based Drug Delivery for Infectious Diseases

Dr. Vinod Kumar Rajana

Dr. Vinod Kumar Rajana, Assistant Professor of Pharmaceutics, specializes in nanotechnology, bioassays, and infectious disease research. With expertise in nanoparticle synthesis, biotechnology, and drug delivery, his work integrates green chemistry with pharmaceutical innovation to develop sustainable, low-cost nanomaterials for topical antifungal and anticancer therapies, water purification, and biomedical applications.

3

Commissioning the 505(b)(2) Pathways in Hastening the Clinical Translation of Various Drugs via Nanotechnological Approaches

Saurabh Srivastava

Saurabh Srivastava is Associate Professor in Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. He carries more than 15 years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Wockhardt research centre and Dr. Reddy’s Laboratories for development and commercialisation of various NDA and ANDA based products for different regulated markets. He is actively involved in execution of several Industrial and Govt. aided research projects for establishment of novel differentiated (505 b 2) product development. He has 02 Commercial Products, 10 International and National Patents, 01 Edited book, 10 Book chapters along with 25 research publications in Journals of International repute to his credit.

 

Saurabh Shah

Saurabh Shah is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Hyderabad. He has published 2 research papers, 4 review articles and 2 book chapters in renowned journals. His research focus lies in hastening the clinical translation of nanomedicine-based products from bench to bedside. He has also been involved in numerous industry research and development projects from laboratory to pilot scale up.

 

4

Untapped Opportunities in Southeast Asia

Sue Lee

Sue Lee has worked for World Courier for 25 years. During this time she has experienced a variety of customer service and operational functions, including the setting up of numerous, multi-national, clinical sites for the transportation of biological samples. She orchestrated the shipping of thousands of shipments with very specific temperature requirements to a host of challenging locations, and each presenting their own obstacles and dilemmas.

5

Architecting the Modern MICC for Life Sciences GCCs

Tansshuman Das

Tanshuman Das is a life sciences technology and commercial leader with 17+ years of experience across pharmacovigilance, AI, CRO services and drug safety technology. He leads Sales & Marketing at Synapmed and focuses on translating AI and intelligent automation into practical, scalable solutions for life sciences organisations.

press releasesRead more...

First FDA Breakthrough Therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

Clarity PharmaceuticalsASX CU Clarity or Company a clinicalstage radiopharmaceutical company with a mission to develop nextgeneration products that improve treatment outcomes for patients with cancer is pleased to announce that

Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program

Pfizer Inc NYSE PFE and Blackstone Life Sciences Blackstone today announced a strategic cofunding agreement under which funds managed by Blackstone will pay up to a total of billion of development

Circio and Solid Biosciences enter collaboration to evaluate circVec and POLARIS-101 technology for Genetic Heart Disease

Circio Holding ASA OSE CRNA a biotechnology company developing novel circular RNA expression technology for gene and cell therapy today announces a research collaboration with Solid Biosciences Inc

EirGenix and Merck enter Partnership to Strengthen Global Biologics Development Through Integrated BioReliance® Testing and Regulatory Support

EirGenix Inc and Merck have signed a nonlegally binding memorandum of understanding MOU to support EirGenixs IND and BLA enabling biologics pipeline development The MOU outlines Merck as one of EirGenixs preferred contract testing services vendors providing comprehensive BioReliance services

ProBio Enters Exclusive Global Licensing Agreement with AbTis to Develop Next-Generation ADC Asset

ProBio a global contract research development and manufacturing organization CRDMO today announced that it has entered into an exclusive global licensing agreement with AbTis Co Ltd

AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder

In a world where patients with CDKL deficiencies can suffer to epileptic seizures a day a contract biopharmaceutical manufacturer and a parentfounded foundation will partner on earlystage

EventsRead more...

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

LATEST NEWSRead more...

Immuneering Enters into Collaboration with Astellas to Evaluate Combination Therapies for Pancreatic Cancer

Immuneering has entered into a clinical trial collaboration and supply agreement with Astellas Pharma to evaluate investigational combination therapies for patients with pancreatic cancer

Eppendorf Invests €40 Million in New Manufacturing Facility in Penang, Malaysia

Eppendorf has started construction of a new manufacturing facility at Bandar Cassia Technology Park in Penang Malaysia

Lilly Invests US$3.5 Billion in New Manufacturing Facility for Obesity Medicines in Pennsylvania

Eli Lilly and Company has started construction of a US billion manufacturing facility in Lehigh Valley Pennsylvania as part of its plans to expand medicine production in the United States The new site is one of manufacturing facilities

Natera Enters into Collaboration with Incyte for Phase II Trial in Colorectal Cancer

Natera a precision medicine company has entered into a clinical collaboration with Incyte to support a new Phase II study evaluating an investigational treatment for colorectal cancer CRC

Shionogi Enters into Licence Agreement with Link for Antibiotic Cefiderocol

Shionogi has entered into a licence agreement with Link Healthcare Singapore to develop and commercialise cefiderocol in Singapore and Malaysia

IDEL Therapeutics Partners with Daiichi Sankyo to Develop Multi-Drug Conjugates for Solid Tumours

IDEL Therapeutics has entered into a global research collaboration with Daiichi Sankyo to evaluate a multidrug conjugate MDC using iDELs synthetic shuttle platform for the treatment of selected solid tumours The multiyear collaboration will focus on the preclinical evaluation of a new class of MDCs...